<DOC>
	<DOCNO>NCT00202306</DOCNO>
	<brief_summary>This study investigate neuroprotective property low-dose lithium young individual ultra-high risk developping first psychotic episode . Fourty individual symptom emerge psychotic disorder ( without meet threshold full-blown mental illness ) treat low dose lithium ( third dose usually use treat acute mania ) . We assess progression condition individual montly base year . We behavioural , cognitive imaging assessment prior start treatment , three month one year . We hope demonstrate low dose lithium stop even reverse progression disease . We expect behavioral , cognitive vivo brain image parameter individual treat low dose lithium improve , compare monitoring group .</brief_summary>
	<brief_title>Indicated Prevention Psychotic Disorders With Low-dose Lithium</brief_title>
	<detailed_description>To investigate whether low-dose lithium effective agent indicate prevention amongst subject ultra-high risk develop psychotic disorder . This aim achieve treat high-risk patient population low-dose lithium ( 450mg/day ) investigating effect use clinical , neuropsychological , neuroimaging cell biological approach . We recruit 30 patient consider ultra-high risk develop first psychotic episode , currently receive treatment Personal Assessment Crisis Evaluation ( PACE ) clinic Melbourne , Australia . PACE criterion identify patient high risk include subject family history psychosis decrease functioning ( 30 % GAF ) AND/OR attenuate psychotic symptom AND/OR brief psychotic symptom ( BLIPS ) resolve without treatment . Patients give inform consent receive treatment slow release form low dose lithium period year , plus supportive therapy . Patients consent receive supportive therapy . Assessments conduct baseline , twelve week one year post-recruitment . Assessments include cognitive functioning , structural MRI , 1H-MRS 3Tesla cell biological parameter ( bcl-2 , AP-1 ; NIMH , Washington DC ) . In addition , patient see monthly basis clinical interview , cover psychopathology , global functioning , quality life .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Attenuated psychotic symptom Selflimited brief psychotic episode Family History psychosis decrease function last year Organic cause subthreshold psychotic symptom ( eg . epilepsy ) More one week neuroleptic treatment</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>risk mental state</keyword>
	<keyword>prodrome</keyword>
	<keyword>ultra high risk</keyword>
	<keyword>first episode psychosis</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>bipolar disorder</keyword>
</DOC>